Technical Articles

TCR-T cell
工程化IL-21受体增强TCR-T细胞抗肝细胞癌效力的创新策略
Innovative Strategy for Engineering IL-21 Receptor to Enhance the Efficacy of TCR-T Cells Against Hepatocellular Carcinoma
发布时间 2026-02-10
Hepatocellular carcinoma is the most common primary liver cancer and has limited response to conventional therapies. Adoptive T cell therapies (such as TCR-T therapy) have shown significant efficacy in hematologic malignancies.
View details
  • Cancer
  • IL-21R
  • TCR-T cell
  • Hepatocellular carcinoma
Total 1
  • 1
Go to
UA
Link：
Products
Application
Cell FactorTarget Proteins
Custom Services
Custom Protein Expression ServicesCustom SPR Services
About Us
PromotionTechnical ArticlesProduct ApplicationFAQsCitationsAbout Us
We Media：
Facebook Linkedin YouTube X Thraeds Pinterest
©2021-2026 all rights reserved UA Biotechnology Co.,Ltd.
Privacy Policy
网站备案号 浙ICP备2022019033号-2 浙公网安备33010202004867号
 Business license (three certificates in one)
Tel：+86-25-56221161
E-mail：order@ua-bio.com
All products sold on this website shall not be used for clinical diagnosis or treatment of humans or animals, and shall only be used for non-medical purposes such as industrial or scientific research.